$GTHP

GUIDED THERAPEUTICS INC

CIK:0000924515|SEC Filings

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2026	Jun. 30, 2025	Jun. 30, 2026	Jun. 30, 2025
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited)
Sales - devices and disposables	$ 0	$ 117	$ 0	$ 117
Cost of goods sold	0	38	0	38
Gross profit	0	79	0	79
Operating expenses:
Research and development	34	133	78	207
Sales and marketing	23	51	45	124
General and administrative	423	658	878	924
Gain on remeasurement of deferred compensation conversion liability	(2)	0	(222)	0
Total operating expenses	478	842	779	1,255
Loss from operations	(478)	(763)	(779)	(1,176)
Other income (expenses):
Interest expense	(136)	(157)	(287)	(303)
Inducement charge for warrants issued	0	0	(78)	0
Change in fair value of derivative liability	9	30	22	83
Gain from forgiveness of debt	0	15	3	31
Loss on extinguishment of debt	0	0	0	(32)
Other income	0	64	14	161
Total other income (expense)	(127)	(48)	(326)	(60)
Loss before income taxes	(605)	(811)	(1,105)	(1,236)
Provision for income taxes	0	0	0	0
Net loss	(605)	(811)	(1,105)	(1,236)
Deemed dividend for warrant exchanges	0	0	(510)	0
Preferred stock dividends adjustment	1	(45)	(2)	(83)
NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS	$ (604)	$ (856)	$ (1,617)	$ (1,319)
NET LOSS PER SHARE ATTRIBUTABLE TO COMMON STOCKHOLDERS
Basic	$ (0.01)	$ (0.01)	$ (0.02)	$ (0.02)
Diluted	$ (0.01)	$ (0.01)	$ (0.02)	$ (0.02)
Weighted average shares outstanding
Basic	96,536	78,838	92,707	73,594
Diluted	96,536	78,838	92,707	73,594

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2026	Jun. 30, 2025
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (1,105)	$ (1,236)
Adjustments to reconcile net loss to net cash used in operating activities:
Bad debt expense	0	1
Depreciation	4	5
Amortization of debt issuance costs and discounts	88	135
Stock based compensation	79	330
Change in fair value of derivatives	(22)	(83)
Gain on remeasurement of deferred compensation conversion liability	(222)	0
Amortization of lease right-of-use-asset	46	47
Inducement charge for warrants issued	78	0
Gain from forgiveness of debt	(3)	(31)
Loss on extinguishment of debt	0	32
Other non-cash expenses	12	13
Change in operating assets and liabilities:
Accounts receivable	0	(7)
Inventory	(52)	38
Other current assets	79	150
Accounts payable and accrued liabilities	95	327
Lease liabilities	(13)	(51)
Deferred revenue	0	(170)
NET CASH USED IN OPERATING ACTIVITIES	(936)	(500)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from warrant exercises	980	0
Proceeds from the issuance of notes payable	295	355
Payments made on notes payable	(343)	(218)
Payments made on notes payable issued to related parties	(2)	0
Payments of debt issuance costs	(45)	(45)
Proceeds from issuance of common stock and warrants in private placement offerings	0	205
NET CASH PROVIDED BY FINANCING ACTIVITIES	885	297
NET CHANGE IN CASH AND CASH EQUIVALENTS	(51)	(203)
Cash at beginning of period	63	388
CASH AT END OF PERIOD	12	185
SUPPLEMENTAL DISCLOSURE FOR OPERATING ACTIVITIES:
Cash paid for interest	28	25
SUPPLEMENTAL DISCLOSURE FOR NON-CASH INVESTING AND FINANCING ACTIVITIES:
Dividends on preferred stock	2	83
Deemed dividend for warrant exchanges	510	0
Common stock issued for payment of accrued dividends	77	108
Conversion of Preferred Stock Series C to common stock	0	105
Conversion of Preferred Stock Series C1 to common stock	0	109
Conversion of Preferred Stock Series C2 to common stock	0	439
Conversion of Preferred Stock Series D to common stock	0	127
Conversion of Preferred Stock Series E to common stock	95	0
Conversion of Preferred Stock Series F to common stock	591	0
Conversion of Preferred Stock Series F-2 to common stock	215	37
Conversion of debt and accrued interest into common stock	126	0
Warrants issued with debt	11	8
Inception of derivative liability	$ 21	$ 25

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Jun. 30, 2026	Dec. 31, 2025
Current Assets:
Cash and cash equivalents	$ 12	$ 63
Accounts receivable, net of allowance for credit losses of $4 at June 30, 2026 and December 31, 2025	4	4
Inventory, net of reserves of $818 at June 30, 2026 and December 31, 2025	500	448
Other current assets	11	90
Total current assets	527	605
Non-Current Assets:
Property and equipment, net	11	16
Operating lease right-of-use asset, net of amortization	640	686
Other assets	17	17
Total non-current assets	668	719
TOTAL ASSETS	1,195	1,324
Current Liabilities:
Accounts Payable	2,347	2,416
Accounts payable, related parties	32	31
Accrued liabilities	1,242	1,170
Deferred compensation conversion liability, at fair value	326	548
Deferred revenue	189	189
Current portion of lease liability	81	45
Current portion of long-term debt, related parties	434	621
Short-term notes payable	36	82
Short-term convertible notes, net of discounts	296	347
Short-term convertible debt in default	1,150	1,150
Derivative liability at fair value	36	37
Total current liabilities	6,169	6,636
Long-Term Liabilities
Long-term lease liability	602	651
Long-term notes payable	11	23
Long-term debt, related parties	176	20
Total long-term liabilities	789	694
Total liabilities	6,958	7,330
STOCKHOLDERS' DEFICIT:
Common stock, $.001 par value; 500,000 shares authorized, 96,537 and 86,154 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively.	3,481	3,471
Additional paid-in capital	148,843	146,092
Treasury stock at cost	(132)	(132)
Accumulated deficit	(158,672)	(157,055)
Total stockholders' deficit	(5,763)	(6,006)
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT	1,195	1,324
Series C Preferred Stock [Member]
STOCKHOLDERS' DEFICIT:
Preferred stock, value	0	0
Series C1 Convertible Preferred Stock [Member]
STOCKHOLDERS' DEFICIT:
Preferred stock, value	61	61
Series C2 Preferred Stock [Member]
STOCKHOLDERS' DEFICIT:
Preferred stock, value	0	0
Series D Preferred Stock [Member]
STOCKHOLDERS' DEFICIT:
Preferred stock, value	18	18
Series F Preferred Stock [Member]
STOCKHOLDERS' DEFICIT:
Preferred stock, value	226	817
Series F-2 Preferred Stock [Member]
STOCKHOLDERS' DEFICIT:
Preferred stock, value	223	438
Series E Preferred Stock [Member]
STOCKHOLDERS' DEFICIT:
Preferred stock, value	$ 189	$ 284